Literature DB >> 34737067

Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.

Friederike Knipping1, Gregory A Newby2, Cindy R Eide1, Amber N McElroy1, Sarah C Nielsen1, Kyle Smith1, Yongxing Fang3, Tatjana I Cornu4, Caroline Costa5, Alejandra Gutierrez-Guerrero5, Samuel P Bingea1, Colby J Feser1, Benjamin Steinbeck1, Keli L Hippen1, Bruce R Blazar1, Anton McCaffrey6, Claudio Mussolino4, Els Verhoeyen7, Jakub Tolar1, David R Liu2, Mark J Osborn8.   

Abstract

Disruption of CCR5 or CXCR4, the main human immunodeficiency virus type 1 (HIV-1) co-receptors, has been shown to protect primary human CD4+ T cells from HIV-1 infection. Base editing can install targeted point mutations in cellular genomes, and can thus efficiently inactivate genes by introducing stop codons or eliminating start codons without double-stranded DNA break formation. Here, we applied base editors for individual and simultaneous disruption of both co-receptors in primary human CD4+ T cells. Using cytosine base editors we observed premature stop codon introduction in up to 89% of sequenced CCR5 or CXCR4 alleles. Using adenine base editors we eliminated the start codon in CCR5 in up to 95% of primary human CD4+ T cell and up to 88% of CD34+ hematopoietic stem and progenitor cell target alleles. Genome-wide specificity analysis revealed low numbers of off-target mutations that were introduced by base editing, located predominantly in intergenic or intronic regions. We show that our editing strategies prevent transduction with CCR5-tropic and CXCR4-tropic viral vectors in up to 79% and 88% of human CD4+ T cells, respectively. The engineered T cells maintained functionality and overall our results demonstrate the effectiveness of base-editing strategies for efficient and specific ablation of HIV co-receptors in clinically relevant cell types.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Base editing; CCR5; CRISPR/Cas9; CXCR4; HIV; HSC

Mesh:

Substances:

Year:  2021        PMID: 34737067      PMCID: PMC8753564          DOI: 10.1016/j.ymthe.2021.10.026

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  73 in total

1.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

2.  CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations.

Authors:  Cem Kuscu; Mahmut Parlak; Turan Tufan; Jiekun Yang; Karol Szlachta; Xiaolong Wei; Rashad Mammadov; Mazhar Adli
Journal:  Nat Methods       Date:  2017-06-05       Impact factor: 28.547

3.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

4.  Therapeutic base editing of human hematopoietic stem cells.

Authors:  Jing Zeng; Yuxuan Wu; Chunyan Ren; Jasmine Bonanno; Anne H Shen; Devlin Shea; Jason M Gehrke; Kendell Clement; Kevin Luk; Qiuming Yao; Rachel Kim; Scot A Wolfe; John P Manis; Luca Pinello; J Keith Joung; Daniel E Bauer
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

5.  CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis.

Authors:  Soo-Hyun Chung; Keisuke Seki; Byung-Il Choi; Keiko B Kimura; Akihiko Ito; Noriyuki Fujikado; Shinobu Saijo; Yoichiro Iwakura
Journal:  Arthritis Res Ther       Date:  2010-10-12       Impact factor: 5.156

6.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

7.  Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription.

Authors:  Jordana M Henderson; Andrew Ujita; Elizabeth Hill; Sally Yousif-Rosales; Cory Smith; Nicholas Ko; Taylor McReynolds; Charles R Cabral; Julienne R Escamilla-Powers; Michael E Houston
Journal:  Curr Protoc       Date:  2021-02

8.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.

Authors:  Shengdar Q Tsai; Nhu T Nguyen; Jose Malagon-Lopez; Ved V Topkar; Martin J Aryee; J Keith Joung
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

9.  Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Authors:  Beau R Webber; Cara-Lin Lonetree; Mitchell G Kluesner; Matthew J Johnson; Emily J Pomeroy; Miechaleen D Diers; Walker S Lahr; Garrett M Draper; Nicholas J Slipek; Branden A Smeester; Klaus N Lovendahl; Amber N McElroy; Wendy R Gordon; Mark J Osborn; Branden S Moriarity
Journal:  Nat Commun       Date:  2019-11-19       Impact factor: 14.919

10.  Continuous evolution of SpCas9 variants compatible with non-G PAMs.

Authors:  Shannon M Miller; Tina Wang; Peyton B Randolph; Mandana Arbab; Max W Shen; Tony P Huang; Zaneta Matuszek; Gregory A Newby; Holly A Rees; David R Liu
Journal:  Nat Biotechnol       Date:  2020-02-10       Impact factor: 54.908

View more
  3 in total

1.  Residues L55 and W69 of Tva Mediate Entry of Subgroup A Avian Leukosis Virus.

Authors:  Yuntong Chen; Suyan Wang; Xinyi Li; Mengmeng Yu; Peng Liu; Lingzhai Meng; Ru Guo; Xiaoyan Feng; Aijing Liu; Xiaole Qi; Kai Li; Li Gao; Qing Pan; Yanping Zhang; Changjun Liu; Hongyu Cui; Xiaomei Wang; Yulong Gao
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

Review 2.  Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.

Authors:  Alexandra Maslennikova; Dmitriy Mazurov
Journal:  Front Cell Infect Microbiol       Date:  2022-05-25       Impact factor: 6.073

Review 3.  Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV.

Authors:  Julian J Freen-van Heeren
Journal:  BioTech (Basel)       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.